Finanzen von Merck & Co Inc (MRK)MRKMerck & Co Inc

Merck & Co Inc (MRK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology-Keytruda, accounting for 48.5% of total sales, equivalent to $7.91B. Other significant revenue streams include Vaccines -Gardasil/Gardasil and Animal Health-Livestock. Understanding this composition is critical for investors evaluating how MRK navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Merck & Co Inc maintains a gross margin of 81.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.55%, while the net margin is 28.01%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MRK converts its operational activities into shareholder value.

In the context of the broader market, MRK competes directly with industry leaders such as ONC and NVS. With a market capitalization of $369.31B, it holds a leading position in the sector. When comparing efficiency, MRK's gross margin of 81.44% stands against ONC's 89.76% and NVS's 75.99%. Such benchmarking helps identify whether Merck & Co Inc is trading at a premium or discount relative to its financial performance.

Merck's gross margin is currently at 74.64%, which is relatively strong, but the recent net income figures show significant losses in 2026, with a net income of -1.34 billion in Q2 2026. The company's revenue has been fluctuating, with a recent quarterly revenue of $16.61 billion in Q2 2026, indicating some stability but also volatility.